Merck Looks To Leverage "Next 10" For Growth: Emerging Markets Earnings Roundup (Part 4)
This article was originally published in PharmAsia News
Executive Summary
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls. Merck & Co., which aims to see one-fourth of its revenue come from emerging markets by 2013, focused investment in best growth drivers and sales efficiency to bolster key products. Merck's emerging markets strategy will focus on maximizing its own brands, leveraging partnerships with low-cost makers and looking for "inter-brand" opportunities.